<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960581</url>
  </required_header>
  <id_info>
    <org_study_id>IAVI T001</org_study_id>
    <nct_id>NCT02960581</nct_id>
  </id_info>
  <brief_title>Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults</brief_title>
  <official_title>A Phase 1 Randomized Placebo-controlled Clinical Trial of the Safety, Pharmacokinetics and Antiviral Activity of PGT121 Monoclonal Antibody (mAb) in HIV-uninfected and HIV-infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center, Boston MA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ragon Institute of MGH, MIT and Harvard, Boston MA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Health, Houston AIDS Research Team (HART), Houston TX</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mills Clinical Research, Los Angeles CA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Orlando Immunology Clinic, Orlando FL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International AIDS Vaccine Initiative</source>
  <brief_summary>
    <textblock>
      This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral
      efficacy of the PGT121 monoclonal antibody for HIV prevention and therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral
      efficacy of the PGT121 monoclonal antibody for HIV prevention and therapy. PGT121 mAb is a
      recombinant human IgG1 monoclonal antibody that targets a V3 glycan-dependent epitope region
      of the HIV envelope protein. PGT121 mAb was chosen for this study because it is potent,
      neutralizes a wide array of HIV viruses, and can prevent and treat simian-human
      immunodeficiency virus (SHIV) in rhesus monkeys.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">July 8, 2019</completion_date>
  <primary_completion_date type="Actual">July 8, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with PGT121 mAb reactogenicity, related AEs and SAEs</measure>
    <time_frame>6 Months post infusion</time_frame>
    <description>The investigators will measure the following endpoints to evaluate the safety and tolerability of PGT121 mAb in HIV-uninfected and HIV-infected adults:
Proportion of participants with moderate or greater reactogenicity (e.g., solicited adverse events) for 3 days following IV infusion of PGT121 mAb.
Proportion of participants with moderate or greater and/or PGT121 mAb-related unsolicited adverse events (AEs), including safety laboratory (biochemical, hematological) parameters, following IV infusion of PGT121 mAb for the first 56 days post administration of Investigational Product.
Proportion of participants with PGT121 mAb-related serious adverse events (SAEs) throughout the study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: elimination half-life (t1/2)</measure>
    <time_frame>6 Months post infusion</time_frame>
    <description>Pharmacokinetics: elimination half-life (t1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Clearance (CL/F)</measure>
    <time_frame>6 Months post infusion</time_frame>
    <description>Pharmacokinetics: Clearance (CL/F)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Volume of distribution (Vz/F)</measure>
    <time_frame>6 months post infusion</time_frame>
    <description>Pharmacokinetics: Volume of distribution (Vz/F)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area under the concentration decay curve (AUC)</measure>
    <time_frame>6 months post infusion</time_frame>
    <description>Pharmacokinetics: Area under the concentration decay curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Impact of viral load and/or ART on PGT121 disposition, volume of distribution, total exposure</measure>
    <time_frame>6 months post infusion</time_frame>
    <description>Pharmacokinetics: Impact of viral load and/or ART on PGT121 disposition, volume of distribution, total exposure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral Activity</measure>
    <time_frame>6 Months post infusion</time_frame>
    <description>Change in plasma HIV-1 RNA levels from baseline (mean of pre-entry and entry values)</description>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected on ART, (&lt;50 cp/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected on ART, (&lt;50 cp/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected on ART, (&lt;50 cp/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-Infected off ART (VL 2x10^3 - 1x10^5 cp/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-Infected off ART (VL 1x10^2 - 2x10^3 cp/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-uninfected participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGT121 3mg/kg IV</intervention_name>
    <description>3mg/kg administered by IV Infusion</description>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_label>Group 2A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGT121 10mg/kg IV</intervention_name>
    <description>10mg/kg administered by IV infusion</description>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_label>Group 2B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGT121 30mg/kg IV</intervention_name>
    <description>30mg/kg administered by IV infusion</description>
    <arm_group_label>Group 1C</arm_group_label>
    <arm_group_label>Group 2C</arm_group_label>
    <arm_group_label>Group 3A</arm_group_label>
    <arm_group_label>Group 3B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PGT121 3mg/kg SC</intervention_name>
    <description>3mg/kg administered by SC injection
Placebo: None</description>
    <arm_group_label>Arm 1D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo (0.9% Sodium Chloride Injection USP (Saline))</intervention_name>
    <arm_group_label>Arm 1D</arm_group_label>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_label>Group 1C</arm_group_label>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_label>Group 2B</arm_group_label>
    <arm_group_label>Group 2C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Group 1 Inclusion Criteria:

          -  HIV-uninfected males or females age 18-50 years old

          -  Willing to maintain low risk behavior for HIV infection

        Group 1 Exclusion Criteria:

          -  confirmed HIV-infection, pregnancy or lactation, significant acute or chronic disease
             and clinically significant laboratory abnormalities

        Group 2 Inclusion Criteria:

          -  HIV-infected males or females age 18-65 years old

          -  On a stable antiretroviral regimen with HIV-1 RNA plasma level &lt;50 copies/ml, CD4 cell
             count greater than or equal to 300 cells/uL

        Group 2 Exclusion Criteria:

          -  history of AIDS-defining illness within the previous 5 years, significant acute or
             chronic medical condition other than HIV infection, and clinically significant
             laboratory abnormalities

        Group 3 Inclusion Criteria:

          -  HIV-infected males or females age 18-65

          -  Not on antiretroviral therapy for &gt; 6 months with detectable HIV-1 viral load between
             100 and 100,000 copies/ml, CD4 cell count greater than or equal to 300 cells/uL

        Group 3 Exclusion Criteria:

          -  history of AIDS-defining illness within the previous 5 years, significant acute or
             chronic medical condition other than HIV infection, and clinically significant
             laboratory abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Stephenson, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center, Center for Virology and Vaccine Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boris Juelg, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ragon Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://iavi.org</url>
    <description>International AIDS Vaccine Initiative</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

